Mesenchymal stem cells that are multipotent and are adult cells can differentiate into tissues of mesodermal origin such as adipocytes and osteoblasts. Mesenchymal stem cells is the primary attraction in the regenerative medicine research. These cells have the ability to replicate itself and replace damaged or dead tissues. Although the primary mechanism of action of Allogeneic Mesenchymal stem cells is not yet been fully understood, Allogeneic Mesenchymal stem cells is being explored for humans significantly due to the potential and ability to treat a number of chronic diseases in animals. A number of studies have shown mesenchymal stem cells to protect cells from injury and also directly supports tissue repair. Initial studies showed that both autologous and allogeneic mesenchymal stem cells therapy did not undergo immune rejection.
Allogeneic Mesenchymal stem cells can be used for a number of applications. Some of the applications include Allogeneic Mesenchymal stem cells for ostesrthritis, multiple sclerosis, certain cardiovascular diseases and other similar conditions. Although the source of mesenchymal stem cells for Allogeneic Mesenchymal stem cells are primarily derived from bone marrow and adipose tissues other sources are been researched that include muscles, skin, endometrium, synovial fluid and amniotic tissues among others.
Bone marrow is the most common source of mesenchymal stem cells that is used for Allogeneic Mesenchymal stem cells. The bone marrow is generally collected by the bone marrow aspiration method from the hip bone. The collected bone marrow cells are then injected into the affected area of the patient. The procedure takes about an hours’ time with little or no restrictions post procedure and may result in a dull pain that fades away within a few days. However this procedure has a high risk of infection in the bone and thus is required to be performed in highly sterile conditions. Most Allogeneic Mesenchymal stem cells procedures are conducted in hospitals, specialty surgical centers and ambulatory surgical centers.
Scientists and the FDA have struggled with this lack of specificity, yet has successfully generated hundreds of clinical trials that are investigate Allogeneic Mesenchymal stem cells for the treatment of a number of chronic ailments in humans.
The global market for Allogeneic Mesenchymal stem cells is segmented on basis of application and geography.
Based on the application, the global Allogeneic Mesenchymal stem cells market is segmented into:
Based on the Source of Cells, the global Allogeneic Mesenchymal stem cells market is segmented into:
Based on the end users, the global Allogeneic Mesenchymal stem cells market is segmented into:
The Allogeneic Mesenchymal stem cells market is anticipated to grow at a tremendous rate. However, legal and regulatory issues along with high risk of procedure hinder the adoption and growth of the market significantly. Furthermore the results of Allogeneic Mesenchymal stem cells are generally seen in conditions that have been aggravated considerably. However, advancement in technology is expected surge the development of safer and effective Allogeneic Mesenchymal stem cells that will boost the growth of the market during the forecast period. Other factors that drive the growth of the Allogeneic Mesenchymal stem cells market are the increase in research funding, initiates by the government for stem cell research and adapting regulatory guidelines.
North America Allogeneic Mesenchymal stem cells market is expected to hold the maximum market together in the global Allogeneic Mesenchymal stem cells market. This is due to rapid adoption of stem cell technologies and therapies in the region. However increased research activities and changing regulations in countries like China, Japan and India is expected to drive the growth of the Allogeneic Mesenchymal stem cells market at a significantly fast rate throughout the forecast period.
Some of the key players operating in the Allogeneic Mesenchymal stem cells market are Aastrom Biosciences, Inc. Mesoblast Ltd., Celgene Corporation, and StemCells, Inc.
The report covers exhaustive analysis on:
Regional analysis includes